Evaluation of the Utility of Vial Packaging to Reduce Occupational Exposure to Antineoplastic Drugs in Preventing Breakages and Scattering

References

1. 1.↵
   1. Polovich M.,
   2. Olsen M. M.

   Safe Handling of Hazardous Drugs, 3rd ed.; Polovich M., Olsen M. M., Eds.; Oncology Nursing Society: Pittsburgh, PA, 2017, pp 3–4.
2. 2.↵
   Japanese Society of Medical Oncology, Japanese Society of Pharmaceutical Oncology, Japanese Society of Cancer Nursing. JSCN/JSMO/JASPO Guidelines for Safe Handling of Cancer Chemotherapy Drugs, 1st ed; Kanehara & Co., Ltd: Tokyo, Japan, 2015.
3. 3.↵
   Japanese Society of Medical Oncology, Japanese Society of Pharmaceutical Oncology, Japanese Society of Cancer Nursing. JSCN/JSMO/JASPO Guidelines for Safe Handling of Cancer Chemotherapy Drugs, 2nd ed; Kanehara & Co., Ltd: Tokyo, Japan, 2019.
4. 4.↵
   National Institute for Occupational Safety and Health. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings; NIOSH—Publications Dissemination: Cincinnati, OH, 2004; pp 31–32.
5. 5.↵
   U.S. Pharmacopeial Convention. USP General Chapter <800>Hazardous Drugs—Handling in Healthcare Settings. Reprinted from USP 40—NF 35, Second Supplement, 2017, p. 2. USP web site. https://www.usp.org/sites/default/files/usp/document/our-work/healthcare-quality-safety/general-chapter-800.pdf (accessed June 20, 2020).
6. 6.↵
   National Institute for Occupational Safety and Health. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings; NIOSH—Publications Dissemination: Cincinnati, OH, 2004; p 33.
7. 7.↵
   National Institute for Occupational Safety and Health. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016. CDC web site. https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf?id=10.26616/NIOSHPUB2016161 (accessed June 20, 2020).
8. 8.↵
   National Institute for Occupational Safety and Health. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings; NIOSH—Publications Dissemination: Cincinnati, OH, 2004; pp 3–4.
9. 9.↵
   1. Polovich M.

   1. Olsen M. M.

   1. LeFebvre K. B.

   Chemotherapy and Biotherapy Guidelines and Recommendations for Practice, 4th ed.; Polovich M.; Olsen M. M.; LeFebvre K. B., Eds.; Oncology Nursing Society: Pittsburgh, PA, 2014.
10. 10.↵
    1. Sessink P. J. M.,
    2. Kroese E. D.,
    3. van Kranen H. J.,
    4. Bos R. P.

    Cancer Risk Assessment for Health Care Workers Occupationally Exposed to Cyclophosphamide. Int. Arch. Occup. Environ. Health 1995, 67 (5), 317–323.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    National Institute for Occupational Safety and Health. Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings; NIOSH—Publications Dissemination: Cincinnati, OH, 2004; p 18.
12. 12.↵
    American Society of Health-System Pharmacists. ASHP Guidelines on Handling Hazardous Drugs, ASHP, 2006; p 80.
13. 13.↵
    International Society of Oncology Pharmacy Practitioners Standards Committee (ISOPP), ISOPP Standards of Practice. Safe Handling of Cytotoxics. J. Oncol. Pharm. Pract. 2007, 13 (Suppl): 1–81.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Polovich M.,
    2. Olsen M. M.

    Safe Handling of Hazardous Drugs, 3rd ed.; Polovich M., Olsen M. M., Eds.; Oncology Nursing Society: Pittsburgh, PA, 2017, pp 54–58.
15. 15.↵
    Occupational Safety and Health Administration. V.H. Spills. Controlling Occupational Exposure to Hazardous Drugs, 2016. OSHA web site. https://www.osha.gov/SLTC/hazardousdrugs/controlling_occex_hazardousdrugs.html (accessed June 20, 2020).
16. 16.↵
    U.S. Pharmacopeial Convention. USP General Chapter <800>Hazardous Drugs—Handling in Healthcare Settings. Reprinted from USP 40—NF 35, Second Supplement, 2017, p. 11. USP web site. https://www.usp.org/sites/default/files/usp/document/our-work/healthcare-quality-safety/general-chapter-800.pdf (accessed June 20, 2020).
17. 17.↵
    1. Kobayashi Y.,
    2. Iwane Y.,
    3. Nakanishi H.

    Evaluation of Shatter-Resistance of Surface-Protected Vial (Onco-Tain^TM Vial) for Preventing Occupational Exposures to Antineoplastic Drugs. Jpn. J. Pharm. Health Care Sci. 2014, 40 (6), 352–359.

    OpenUrl
18. 18.↵
    The Ministry of Health, Labour and Welfare of Japan, G7 Containers and Package: Basic Requirements and Terms for the Packaging of Pharmaceutical Products. In: The Japanese Pharmacopoeia, 17th Edition, MHLW: Tokyo, 2016; pp 2438–2442.
19. 19.↵
    1. Polovich M.,
    2. Olsen M. M.

    Safe Handling of Hazardous Drugs, 3rd ed.; Polovich M., Olsen M. M., Eds.; Oncology Nursing Society: Pittsburgh, PA, 2017, pp 6–17.
20. 20.↵
    1. Selevan S. G.,
    2. Lindbohm M.-L.,
    3. Hornung R. W.,
    4. Hemminki K.

    A Study of Occupational Exposure to Antineoplastic Drugs and Fetal Loss in Nurses. N. Engl. J. Med. 1985, 313 (19), 1173–1178.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Stucker I.,
    2. Caillard J. F.,
    3. Collin R.,
    4. Gout M.,
    5. Poyen D.,
    6. Hemon D.

    Risk of Spontaneous Abortion among Nurses Handling Antineoplastic Drugs. Scand. J. Work. Environ. Health 1990, 16 (2), 102–107.

    OpenUrlCrossRefPubMedWeb of Science